| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046045283 |
| P356 | DOI | 10.1038/80466 |
| P698 | PubMed publication ID | 11017144 |
| P5875 | ResearchGate publication ID | 12306887 |
| P50 | author | Christian H Brandts | Q59691122 |
| P2093 | author name string | F McCormick | |
| B C Hann | |||
| W M Korn | |||
| A S Chung | |||
| E M Lipner | |||
| C H Biederer | |||
| S J Ries | |||
| P2860 | cites work | Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53 | Q22009955 |
| DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts | Q24336806 | ||
| P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2 | Q24650492 | ||
| The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 | Q28266637 | ||
| Clonal analysis of human colorectal tumors | Q28283169 | ||
| Requirement for p53 and p21 to sustain G2 arrest after DNA damage | Q29547667 | ||
| mdm2 expression is induced by wild type p53 activity | Q29618316 | ||
| Nucleolar Arf sequesters Mdm2 and activates p53 | Q29620244 | ||
| p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection | Q33785919 | ||
| Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. | Q33888123 | ||
| The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. | Q33889383 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection | Q34562704 | ||
| E1A signaling to p53 involves the p19(ARF) tumor suppressor | Q35206764 | ||
| INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. | Q35208402 | ||
| Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 | Q36174385 | ||
| Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport | Q36894173 | ||
| Implications of the p53 tumor-suppressor gene in clinical oncology. | Q40500755 | ||
| Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells | Q40928320 | ||
| p53-dependent cell death/apoptosis is required for a productive adenovirus infection | Q41009439 | ||
| Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor | Q41192780 | ||
| Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines | Q41520126 | ||
| Mdm2: keeping p53 under control | Q41585894 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| p14ARF links the tumour suppressors RB and p53. | Q55067966 | ||
| Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy | Q71563602 | ||
| p53 status and the efficacy of cancer therapy in vivo | Q72839445 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| P304 | page(s) | 1128-1133 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) | |
| P478 | volume | 6 |
| Q34710450 | (Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease |
| Q34764233 | 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells |
| Q35868661 | A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation |
| Q28477181 | A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition |
| Q39771175 | A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. |
| Q53582142 | Activated Notch1 interacts with p53 to inhibit its phosphorylation and transactivation. |
| Q35000513 | Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q35043111 | Adenoviral vectors: systemic delivery and tumor targeting |
| Q35911903 | An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. |
| Q46624928 | An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer |
| Q39602482 | Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein |
| Q43930950 | Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells |
| Q24301787 | Antiviral action of the tumor suppressor ARF |
| Q37386616 | Armed replicating adenoviruses for cancer virotherapy |
| Q34572090 | Cancer gene therapy: fringe or cutting edge? |
| Q34225918 | Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? |
| Q34725017 | Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas |
| Q35967313 | Conditionally replicating adenoviruses for cancer treatment. |
| Q55467684 | Designer Oncolytic Adenovirus: Coming of Age. |
| Q44270897 | Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas |
| Q34253427 | Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? |
| Q46113172 | Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin |
| Q35064126 | Emerging cancer-targeted therapies |
| Q37666015 | Emerging roles of p53 and other tumour-suppressor genes in immune regulation |
| Q40551469 | Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. |
| Q39685569 | Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. |
| Q34417562 | Exploiting genetic alterations to design novel therapies for cancer |
| Q40416354 | Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. |
| Q37340383 | Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5. |
| Q35648549 | Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. |
| Q36150432 | Gene- and immunotherapy for hepatocellular carcinoma |
| Q34091002 | Heterochromatin silencing of p53 target genes by a small viral protein |
| Q35043094 | Intravascular adenoviral agents in cancer patients: lessons from clinical trials |
| Q37290808 | Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein |
| Q35027802 | Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond |
| Q35161842 | MDM2 promotes ubiquitination and degradation of MDMX |
| Q43966872 | Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors |
| Q42544861 | Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q41036948 | Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function |
| Q40700227 | ONYX-015 selectivity and the p14ARF pathway |
| Q34115253 | ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus |
| Q40711818 | Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus |
| Q26777406 | Oncolytic Replication of E1b-Deleted Adenoviruses |
| Q92052373 | Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice |
| Q37733550 | Oncolytic adenoviruses expressing interleukin: a novel antitumour approach |
| Q35040863 | Oncolytic adenoviruses for treatment of brain tumours |
| Q40231011 | Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model |
| Q34452020 | Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials |
| Q40031241 | Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus |
| Q33924550 | Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses |
| Q78595329 | Oncolytic viruses |
| Q34234147 | Oncolytic viruses and cancer therapy |
| Q35902523 | Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. |
| Q38020107 | Oncolytic viruses in the treatment of cancer: a review of current strategies |
| Q35120176 | Progress and problems with the use of viral vectors for gene therapy |
| Q39858149 | RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses |
| Q40663884 | Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein |
| Q28247699 | Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation |
| Q34393001 | Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway |
| Q33865835 | Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway |
| Q40011883 | Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants |
| Q34293607 | Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer |
| Q35912403 | Replication-selective oncolytic viruses in the treatment of cancer. |
| Q34297058 | Replication-selective virotherapy for cancer: Biological principles, risk management and future directions |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q35091138 | Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. |
| Q46061653 | Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents |
| Q35080295 | Study of suboptimum treatment response: lessons from breast cancer |
| Q37093159 | The feasibility of gene therapy in the treatment of head and neck cancer |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q35904008 | The use of gene therapy in cancer research and treatment |
| Q35779378 | Tissue-specific promoters for cancer gene therapy |
| Q42261523 | Tumor-specific cytolysis caused by an E1B55K-attenuated adenovirus in nasopharyngeal carcinoma is augmented by cisplatin |
| Q44571557 | Tumor-specific intravenous gene delivery using oncolytic adenoviruses |
| Q64378232 | Viral oncolysis |
| Q36318145 | Viruses - seeking and destroying the tumor program |
| Q36254857 | Viruses with deletions in antiapoptotic genes as potential oncolytic agents. |
| Q40358341 | p53 promotes adenoviral replication and increases late viral gene expression |
| Q35569909 | pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis |
Search more.